Reverse transcriptase-polymerase chain reaction for amantadine susceptibility testing of influenza viruses

P. C. Suen*, K. C. Tsao, T. L. Wu, H. C. Ning, T. Z. Liu, S. R. Shin

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

The clinical use of amantadine for influenza A viruses infection is increasing. A novel quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay was developed to determine the IC50 (dose of 50% inhibitory) of amantadine. The traditional amantadine susceptibility testing by plaque inhibition assay took 3 days to observe plaque formation. In contrast, the proposed assay took 3 hours to detect vital RNA. The RT-PCR products can be directly sequenced for screening and identifying the resistant strains.

Original languageEnglish
Pages (from-to)873-878
Number of pages6
JournalBiotechnology Techniques
Volume11
Issue number12
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Dive into the research topics of 'Reverse transcriptase-polymerase chain reaction for amantadine susceptibility testing of influenza viruses'. Together they form a unique fingerprint.

Cite this